Evaxion Biotech AS (EVAX)
1.44
-0.24
(-14.29%)
USD |
NASDAQ |
Nov 15, 16:00
1.40
-0.04
(-2.78%)
After-Hours: 20:00
Evaxion Biotech Research and Development Expense (TTM): 10.50M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 10.50M |
| June 30, 2024 | 10.72M |
| March 31, 2024 | 10.90M |
| December 31, 2023 | 11.92M |
| September 30, 2023 | 13.69M |
| June 30, 2023 | 14.93M |
| March 31, 2023 | 16.10M |
| December 31, 2022 | 17.06M |
| September 30, 2022 | 19.14M |
| Date | Value |
|---|---|
| June 30, 2022 | 19.49M |
| March 31, 2022 | 20.49M |
| December 31, 2021 | 19.58M |
| September 30, 2021 | 16.28M |
| June 30, 2021 | 14.83M |
| March 31, 2021 | 12.28M |
| December 31, 2020 | 10.90M |
| September 30, 2020 | 10.99M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
10.50M
Minimum
Sep 2024
20.49M
Maximum
Mar 2022
14.69M
Average
14.83M
Median
Jun 2021
Research and Development Expense (TTM) Benchmarks
| Ascendis Pharma AS | 385.87M |
| DBV Technologies SA | 83.21M |
| Adaptimmune Therapeutics PLC | 143.17M |
| Akari Therapeutics PLC | 8.848M |
| Biodexa Pharmaceuticals PLC | -- |